| scholarly article | Q13442814 |
| P356 | DOI | 10.1042/CS20110369 |
| P698 | PubMed publication ID | 21966999 |
| P2093 | author name string | Ann Donald | |
| Phil Chowienczyk | |||
| Lindsey Tilling | |||
| Brian Clapp | |||
| Joanne Hunt | |||
| P2860 | cites work | The CD40/CD154 receptor/ligand dyad | Q28202756 |
| Direct cardiac actions of erythropoietin (EPO): effects on cardiac contractility, BNP secretion and ischaemia/reperfusion injury | Q28579901 | ||
| Recombinant human erythropoietin protects the myocardium from ischemia-reperfusion injury and promotes beneficial remodeling | Q34960679 | ||
| Endothelial function and dysfunction. Part II: Association with cardiovascular risk factors and diseases. A statement by the Working Group on Endothelins and Endothelial Factors of the European Society of Hypertension | Q36015782 | ||
| The non-haematopoietic biological effects of erythropoietin | Q37103957 | ||
| In vivo tracking of platelets: circulating degranulated platelets rapidly lose surface P-selectin but continue to circulate and function | Q37273254 | ||
| Functional erythropoietin receptor is undetectable in endothelial, cardiac, neuronal, and renal cells | Q38346748 | ||
| Recombinant human erythropoietin in the treatment of acute ischemic stroke | Q38378327 | ||
| Ischemic preconditioning prevents endothelial injury and systemic neutrophil activation during ischemia-reperfusion in humans in vivo | Q43556471 | ||
| Sustained release of erythropoietin using biodegradable gelatin hydrogel microspheres persistently improves lower leg ischemia. | Q44520062 | ||
| Erythropoietin and hypoxia stimulate erythropoietin receptor and nitric oxide production by endothelial cells. | Q44942679 | ||
| Darbepoetin alfa, a long-acting erythropoietin analog, offers novel and delayed cardioprotection for the ischemic heart | Q45866840 | ||
| Erythropoietin protects from reperfusion-induced myocardial injury by enhancing coronary endothelial nitric oxide production | Q46112203 | ||
| Hearts from rodents exposed to intermittent hypoxia or erythropoietin are protected against ischemia-reperfusion injury | Q47849035 | ||
| A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease | Q50578930 | ||
| Erythropoietin-induced upregulation of endothelial nitric oxide synthase but not vascular endothelial growth factor prevents musculocutaneous tissue from ischemic damage | Q53360970 | ||
| Internalization of CD40 regulates its signal transduction in vascular endothelial cells. | Q54612020 | ||
| Randomized, double-blind, placebo-controlled study to evaluate the effect of two dosing regimens of darbepoetin alfa in patients with heart failure and anaemia | Q57422720 | ||
| Increased circulating hematopoietic and endothelial progenitor cells in the early phase of acute myocardial infarction | Q57589498 | ||
| Erythropoietin is a potent physiologic stimulus for endothelial progenitor cell mobilization | Q58816341 | ||
| P433 | issue | 7 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | endothelium | Q111140 |
| darbepoetin alfa | Q2178381 | ||
| coronary artery disease | Q844935 | ||
| P304 | page(s) | 329-336 | |
| P577 | publication date | 2012-04-01 | |
| P1433 | published in | Clinical Science | Q372419 |
| P1476 | title | Darbepoetin enhances endothelium-dependent vasomotor function in patients with stable coronary artery disease only after preceding ischaemia/reperfusion | |
| P478 | volume | 122 |
| Q46977348 | Natural compound bavachalcone promotes the differentiation of endothelial progenitor cells and neovascularization through the RORα-erythropoietin-AMPK axis |
| Q41113655 | Protective effect of glycyrrhizin on myocardial ischemia/reperfusion injury-induced oxidative stress, inducible nitric oxide synthase and inflammatory reactions through high-mobility group box 1 and mitogen-activated protein kinase expression |
| Q38108537 | What is the role of erythropoietin in acute myocardial infarct? Bridging the gap between experimental models and clinical trials |
Search more.